Objective Over the last two decades preterm babies (neonates with less than 37 weeks of gestational period) have rise tremendously reaching 15 million births worldwide in 2014, and the figures are growing. Anyhow, despite we have been successful at maintaining alive premature babies until their live it’s not at risk, we are failing at solving important side-problems. Preterm babies are at high risk of suffering encephalopathies (brain damage) during the artificial gestational stage on the neonatal intensive-care units (NICUs). In fact, about 20% of babies born before 6.5 months gestation experience lasting brain damage. This leads to lifelong disorders such as attention deficit, autism, cerebral paralysis, and hearing or visual impairments.To early detect cerebral damage in a precise manner it’s necessary to provide real time and accurate measures of cerebral oxygen metabolism and blood flow in the brain. This problem remains unsolved since current commercial solutions provide partial measurements or are extremely invasive. BabyLux will be the first device allowing early detect and manage encephalopathies in preterm-babies in a non-invasive and affordable manner by combining two leading photonic techniques.Our product fall within the sub-segment of “monitoring equipment” for NICUs, which is a € 1.200M market growing at a CARG of 6.5%.BabyLux will be sold at a first commercialization stage to pre-clinical markets (research institutions studying brain damage in neonates). We will proceed in such way since to gain credibility among scientific community, easing the entrance to clinical segments. At a second commercialization stage we will approach clinical segments, in particular hospitals with NICUs. This mixed business model will allow HemoPhotonics to achieve a turnover of € 13 M at 5 years after the project compilation. We are requesting a SMEI Phase 1 to further define and corroborate our business assumptions. Fields of science social scienceseconomics and businessbusiness and managementbusiness models Programme(s) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator HEMOPHOTONICS SL Net EU contribution € 50 000,00 Address Avenida carl friedrich gauss 3 oficina 346 mediterranean technology park 08860 Castelldefels Spain See on map Region Este Cataluña Barcelona Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
